Genentech to Present New Data on Ocrevus (ocrelizumab) in Multiple Sclerosis and Enspryng (satralizumab-mwge) in Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2021

 Ocrevus data to show sustained reduction in disability progression through 8 years for primary progressive multiple sclerosis (PPMS) and 7.5 years for relapsing MS (RMS)

Long-term safety analysis of all clinical trials will reinforce the consistently favorable benefit-risk profile of Ocrevus

Enspryng data to show efficacy and safety sustained over four years of treatment for people living with neuromyelitis optica spectrum disorder (NMOSD)

Study design for SAkuraBONSAI, a new study on disease activity and progression in Enspryng patients, who are treatment naïve or where prior rituximab (or biosimilar) treatment has failed, will be presented

continue

Click to Subscribe for the MS Beacon eNewsletter